Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

U-Ploid Biotechnologies joins the BioEscalator to develop groundbreaking therapeutics that improve egg quality and revolutionise IVF.

Millions of women worldwide face the heartbreaking challenge of age-related infertility, and U-Ploid Biotechnologies is on a mission to transform their lives.

 

Co-founded by Jordan Abdi (CEO), Chloe Charalambous (COO), and Alexandre Webster (CSO), U-Ploid Biotechnologies is dedicated to significantly improving the success rates of IVF leading to a healthy pregnancy. Their approach involves the development of therapeutics designed to radically improve the quality of egg cells in older women and, in doing so, tackle age-related infertility.

 

Selected for the prestigious Accelerate@Babraham program, U-Ploid is "thrilled to join the vibrant BioEscalator community". The company's founders have said they are "highly impressed by the state-of-the-art facilities and resources available at BioEscalator", which will be instrumental in achieving their core milestones over the coming years. They share that "the proximity to the Wolfson Imaging Center is an added advantage for their essential super-resolution microscopy assays".

 

U-Ploid is eager to collaborate with other innovative companies at BioEscalator and contribute to the thriving life science ecosystem. We welcome U-Ploid to the BioEscalator community and look forward to supporting their groundbreaking work.